TY - JOUR
T1 - Immuno-oncologic profiling of renal masses using multiparametric MRI
T2 - a pilot study
AU - Liu, Mira M.
AU - Bane, Octavia
AU - Mu, Xin
AU - Al-Mubarak, Haitham
AU - Abboud, Ghadi
AU - Reddy, Arthi M.
AU - Kennedy, Paul
AU - Robson, Philip
AU - Meilika, Kirolos
AU - Zuluaga, Laura
AU - Horowitz, Amir
AU - Kuhn, Bernd
AU - Thin, Tin Htwe
AU - Garcia-Barros, Monica
AU - Brody, Rachel
AU - Badani, Ketan
AU - Taouli, Bachir
AU - Lewis, Sara
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.
PY - 2025/12/5
Y1 - 2025/12/5
N2 - Purpose Preoperative characterization of renal mass malignancy, subtype, and immuno-oncologic pathology could inform and improve tailored management decisions. We examine multiparametric MRI (mpMRI) for (1) sensitivity to immuno-oncologic markers of the tumor immune microenvironment and (2) classification of tumor malignancy, subtype, and grade. Methods and materials In a prospective, institutional review board-approved single-center study, 40 patients (13 female/27 males, 60.4±10.7years) scheduled to undergo surgical management of solid renal masses underwent preoperative 1.5T MRI. This included T1, multi-b-value diffusion-weighted imaging (DWI as intravoxel incoherent motion (IVIM), and apparent diffusion coefficient (ADC)), R2*, arterial spin labeling (ASL), and dynamic contrast-enhanced (DCE-)MRI. Clear cell likelihood scores (ccLS) were assigned using clinical MR images. Tumor diagnoses were extracted from the surgical histopathology. Logistic regression models were built with leave-one-out cross-validation and bootstrapping. Interobserver measurements were obtained in a subset of 27 patients, and tests–retests were run for 2 patients. Tumors from 18 patients with clear cell renal cell carcinoma (ccRCC) underwent immunohistochemistry for CD3, CD4, CD8, CD68, PD-L1, NKp46, HIF-1α, and CD31. MR biomarkers of immunohistochemistry stains were identified with Pearson’s r correlation, and diagnostic OR for >5%or >15% cells stained positive, by cross-validated univariate logistic regression. Results Of the 40 solid renal masses (mean (range)=32 (8–68) mm), 22 were clear cell, 9 non-clear cell and 9 benign, with 10 Grade 1. IVIM f, D*, and fD* correlated with T cells (CD4, CD3, CD8), while R2* correlated positively with macrophage presence (CD68) and negatively with angiogenesis (CD31). DCE-MRI and ASL negatively correlated with CD68. ASL negatively correlated with CD8 T cells. IVIM D* returned a significant OR for CD68-positive stains (OR=55.0, p<0.001), while ASL renal blood flow returned a significant OR for CD8-positive stains (OR=24.0, p=0.03). mpMRI tumor volume and IVIM D heterogeneity returned the highest A U C 95 % C I = 0.84 ( 0.70,0.98 )) for malignancy. ccLS had the highest A U C ( 95 % C I ) = 0.75 ( 0.56 , 0.92 ) for overall detection of ccRCC, and mpMRI distinguished ccRCC from non-ccRCC with increased IVIM D and ADC with A U C ( 95 % C I ) = 0.95 ( 0.86,1.0 ) ). Conclusion In this pilot study, mpMRI was sensitive to immuno-oncologic biomarkers supporting preoperative MRI as a method of characterizing tumor immune microenvironment, malignancy, and subtype for informed and tailored treatment management.
AB - Purpose Preoperative characterization of renal mass malignancy, subtype, and immuno-oncologic pathology could inform and improve tailored management decisions. We examine multiparametric MRI (mpMRI) for (1) sensitivity to immuno-oncologic markers of the tumor immune microenvironment and (2) classification of tumor malignancy, subtype, and grade. Methods and materials In a prospective, institutional review board-approved single-center study, 40 patients (13 female/27 males, 60.4±10.7years) scheduled to undergo surgical management of solid renal masses underwent preoperative 1.5T MRI. This included T1, multi-b-value diffusion-weighted imaging (DWI as intravoxel incoherent motion (IVIM), and apparent diffusion coefficient (ADC)), R2*, arterial spin labeling (ASL), and dynamic contrast-enhanced (DCE-)MRI. Clear cell likelihood scores (ccLS) were assigned using clinical MR images. Tumor diagnoses were extracted from the surgical histopathology. Logistic regression models were built with leave-one-out cross-validation and bootstrapping. Interobserver measurements were obtained in a subset of 27 patients, and tests–retests were run for 2 patients. Tumors from 18 patients with clear cell renal cell carcinoma (ccRCC) underwent immunohistochemistry for CD3, CD4, CD8, CD68, PD-L1, NKp46, HIF-1α, and CD31. MR biomarkers of immunohistochemistry stains were identified with Pearson’s r correlation, and diagnostic OR for >5%or >15% cells stained positive, by cross-validated univariate logistic regression. Results Of the 40 solid renal masses (mean (range)=32 (8–68) mm), 22 were clear cell, 9 non-clear cell and 9 benign, with 10 Grade 1. IVIM f, D*, and fD* correlated with T cells (CD4, CD3, CD8), while R2* correlated positively with macrophage presence (CD68) and negatively with angiogenesis (CD31). DCE-MRI and ASL negatively correlated with CD68. ASL negatively correlated with CD8 T cells. IVIM D* returned a significant OR for CD68-positive stains (OR=55.0, p<0.001), while ASL renal blood flow returned a significant OR for CD8-positive stains (OR=24.0, p=0.03). mpMRI tumor volume and IVIM D heterogeneity returned the highest A U C 95 % C I = 0.84 ( 0.70,0.98 )) for malignancy. ccLS had the highest A U C ( 95 % C I ) = 0.75 ( 0.56 , 0.92 ) for overall detection of ccRCC, and mpMRI distinguished ccRCC from non-ccRCC with increased IVIM D and ADC with A U C ( 95 % C I ) = 0.95 ( 0.86,1.0 ) ). Conclusion In this pilot study, mpMRI was sensitive to immuno-oncologic biomarkers supporting preoperative MRI as a method of characterizing tumor immune microenvironment, malignancy, and subtype for informed and tailored treatment management.
KW - Biomarker
KW - fMRI / PET
KW - Kidney Cancer
KW - Pathology
KW - Tumor microenvironment - TME
UR - https://www.scopus.com/pages/publications/105024122912
U2 - 10.1136/jitc-2025-012833
DO - 10.1136/jitc-2025-012833
M3 - Article
C2 - 41360428
AN - SCOPUS:105024122912
SN - 2051-1426
VL - 13
JO - Journal for ImmunoTherapy of Cancer
JF - Journal for ImmunoTherapy of Cancer
IS - 12
M1 - e012833
ER -